- Adaptive design clinical trials: current status by disease and trial phase in various perspectives
-
Lee H, Hwang S, Jang IJ, Chung JY, Oh J
- KMID: 2552441
- Transl Clin Pharmacol.
- 2023 Dec;31(4):202-216.
- doi: 10.12793/tcp.2023.31.e21
An adaptive design is a clinical trial design that allows for modification of a structured plan in a clinical trial based on data accumulated during pre-planned interim analyses. This flexible... -
- CITED
-
- Close
- SHARE
-
- Close
- Phage-host-immune system dynamics in bacteriophage therapy: basic principles and mathematical models
-
Chae D
- KMID: 2552439
- Transl Clin Pharmacol.
- 2023 Dec;31(4):167-190.
- doi: 10.12793/tcp.2023.31.e17
Phage therapy is progressively being recognized as a viable alternative to conventional antibiotic treatments, particularly in the context of multi-drug resistant bacterial challenges. However, the intricacies of the pharmacokinetics and... -
- CITED
-
- Close
- SHARE
-
- Close
- Pharmacokinetic properties of a new sustained-release pregabalin tablet in subjects with reduced renal function
-
Park M, Choi S, Han S, Shin W, Kim A, Han S, Kim B, Lim Y, Yoo H
- KMID: 2552443
- Transl Clin Pharmacol.
- 2023 Dec;31(4):226-237.
- doi: 10.12793/tcp.2023.31.e20
A new sustained-release (SR) pregabalin tablet, YHD1119, was formulated for once-daily dosing. In the current study, we aimed to evaluate the pharmacokinetics of YHD1119 tablets in patients with reduced renal... -
- CITED
-
- Close
- SHARE
-
- Close
- Pharmacokinetics of low doses of colchicine in the leukocytes of Japanese healthy individuals
-
Mutoh A, Uehara H, Maeda A, Tokushige A, Higashiuesato Y, Maeda M, Kumagai Y, Ueda S
- KMID: 2552442
- Transl Clin Pharmacol.
- 2023 Dec;31(4):217-225.
- doi: 10.12793/tcp.2023.31.e19
The venerable drug colchicine has garnered significant recent attention due to its endorsement by the United States Food and Drug Administration as an anti-inflammatory medication for cardiovascular diseases. However, the... -
- CITED
-
- Close
- SHARE
-
- Close
- A review of the current state in neointimal hyperplasia development following endovascular intervention and minor emphasis on new horizons in immunotherapy
-
Dinc R
- KMID: 2552440
- Transl Clin Pharmacol.
- 2023 Dec;31(4):191-201.
- doi: 10.12793/tcp.2023.31.e18
Endovascular strategies play a vital role in the treatment of peripheral arterial disease (PAD). However, luminal loss or restenosis after endovascular intervention remains a significant challenge. The main underlying mechanisms... -
- CITED
-
- Close
- SHARE
-
- Close
